Low Toxicity in Inflammatory Bowel Disease Patients Treated With Abdominal and Pelvic Radiation Therapy

被引:25
|
作者
White, Evan C. [1 ]
Murphy, James D. [1 ]
Chang, Daniel T. [1 ]
Koong, Albert C. [1 ]
机构
[1] Stanford Univ, Sch Med, Dept Radiat Oncol, Stanford Canc Inst, Stanford, CA 94305 USA
来源
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2015年 / 38卷 / 06期
关键词
inflammatory bowel disease; toxicity; intensity-modulated radiation therapy (IMRT); RADIOTHERAPY; CANCER; SURGERY; HISTORY; TRIAL; RISK;
D O I
10.1097/COC.0000000000000010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective:To determine the short-term and long-term toxicity of abdominal and pelvic radiation therapy in a cohort of patients with inflammatory bowel disease (IBD). We hypothesize that with newer techniques, such as intensity-modulated radiation therapy (IMRT) and 3-dimensional conformal radiotherapy (3D-CRT), patients with IBD can safely undergo abdominal and pelvic radiation, with low risk for major acute or late toxicity.Materials and Methods:Nineteen consecutive patients with IBD (14 with ulcerative colitis, 5 with Crohn disease) who were treated with abdominal or pelvic external beam radiation therapy at Stanford University from 1997 to 2011 were identified. Fourteen patients were treated with IMRT and 5 were treated with 3D-CRT. Treated sites included prostate (n=8), gastric/esophageal (n=5), rectal/anal (n=3), and liver (n=3) tumors. Charts were reviewed and toxicity was graded according to the Common Terminology Criteria for Acute Events version 4.0. Median follow-up was 32.5 months. Fisher exact test was used to determine if any clinical and/or treatment factors were associated with toxicity outcomes.Results:Acute grade 3 toxicity occurred in 2 patients (11%). Late grade 3 toxicity occurred in 1 patient (6%). Acute grade 2 toxicity occurred in 28% of patients treated with IMRT versus 100% of patients treated with 3D-CRT (P=0.01). Acute grade 2 gastrointestinal toxicity was lower in patients treated with IMRT versus 3D-CRT (14% vs. 100%, respectively, P=0.002). Late grade 2 toxicity occurred in 21% of patients. Higher total dose (Gy) and biologically effective dose (Gy) were associated with increased rates of late grade 2 toxicity (P=0.02 and 0.03, respectively).Conclusions:These data suggest that select patients with IBD can safely undergo abdominal and pelvic radiation therapy. The use of IMRT was associated with decreased acute toxicity. Acute and late severe toxicity rates were low in this patient population with the use of modern radiation techniques.
引用
收藏
页码:564 / 569
页数:6
相关论文
共 50 条
  • [21] Radiation therapy in patients with inflammatory bowel disease and colorectal cancer: Risks and benefits
    Bianca W. Chang
    Aryavarta M. S. Kumar
    Shlomo A. Koyfman
    Matthew Kalady
    Ian Lavery
    May Abdel-Wahab
    International Journal of Colorectal Disease, 2015, 30 : 403 - 408
  • [22] Early dose-dependent cortical thinning of the femoral neck in anal cancer patients treated with pelvic radiation therapy
    Okoukoni, Catherine
    Randolph, David M.
    McTyre, Emory R.
    Kwok, Andy
    Weaver, Ashley A.
    Blackstock, William
    Munley, Michael T.
    Willey, Jeffrey S.
    BONE, 2017, 94 : 84 - 89
  • [23] Toxicity and survival of anal cancer patients treated with intensity-modulated radiation therapy
    Ghareeb, A.
    Paramasevon, K.
    Mokool, P.
    van der Voet, H.
    Jha, M.
    ANNALS OF THE ROYAL COLLEGE OF SURGEONS OF ENGLAND, 2019, 101 (03) : 168 - 175
  • [24] Toxicity of mycophenolate mofetil in patients with inflammatory bowel disease
    Skelly, MM
    Logan, RFA
    Jenkins, D
    Mahida, YR
    Hawkey, CJ
    INFLAMMATORY BOWEL DISEASES, 2002, 8 (02) : 93 - 97
  • [26] Stereotactic body radiation therapy on abdominal-pelvic lymph node oligometastases: a systematic review on toxicity
    van Werkhoven, Lucy A.
    Cammareri, Eugenio
    Hoogeman, Mischa S.
    Nout, Remi A.
    Milder, Maaike T. W.
    Nuyttens, Joost J. M. E.
    ACTA ONCOLOGICA, 2024, 63 : 822 - 832
  • [27] The Role of Vitamin D in Patients with Inflammatory Bowel Disease Treated with Vedolizumab
    Abraham, Bincy P.
    Fan, Christopher
    Thurston, Theresa
    Moskow, Joshua
    Malaty, Hoda M.
    NUTRIENTS, 2023, 15 (22)
  • [28] Postoperative complications of pediatric patients with inflammatory bowel disease treated with vedolizumab
    Zimmerman, Lori A.
    Zalieckas, Jill M.
    Shamberger, Robert C.
    Bousvaros, Athos
    JOURNAL OF PEDIATRIC SURGERY, 2018, 53 (07) : 1330 - 1333
  • [29] Feasibility of Reduced Clinical Monitoring in Patients with Inflammatory Bowel Disease Treated with Thiopurine Therapy
    Fenna M. Jansen
    Lisa J. T. Smits
    Pepijn W. A. Thomas
    Dirk J. de Jong
    Joany E. Kreijne
    Willemijn A. van Dop
    Nathan den Broeder
    Frank Hoentjen
    Digestive Diseases and Sciences, 2023, 68 : 2936 - 2945
  • [30] Intra-abdominal Surgery and Intestinal Syndromes After Pelvic Radiation Therapy
    Bull, Cecilia
    Moren, Amelie Toft
    Skokic, Viktor
    Wilderang, Ulrica
    Malipatlolla, Dilip
    Alevronta, Eleftheria
    Dunberger, Gail
    Sjoberg, Fei
    Bergmark, Karin
    Steineck, Gunnar
    ADVANCES IN RADIATION ONCOLOGY, 2024, 9 (01)